

TTG THE COPY

ΑD	

Retinal Derived Growth Factor: A Regulator of Neural Regeneration and Revascularization in Wound Healing

Annual/Final Report

Dr. John A. Wagner

December 1, 1989

Supported by U.S. Army Medical Research and Development Command Fort Detrick, Frederick, Maryland 21701-5012

Contract No. DAMD17-87-C-7009

Dana-Farber Cancer Institute 44 Binney Street Boston, MA 02115

Approved for public release; distribution unlimited

The findings in this report are not to be construed as an official Department of the Army position unless so designated by other authorized documents.

SECURITY CLASSIFICATION OF THIS P		OCUMENTATIO	N PAGE		Form Approved OMB No. 0704-0188									
1a. REPORT SECURITY CLASSIFICATIO Unclassified	N		16 RESTRICTIVE MARKINGS											
2a. SECURITY CLASSIFICATION AUTH		3 DISTRIBUTION/AVAILABILITY OF REPORT												
2b. DECLASSIFICATION / DOVVNGRADI	LÉ	Approved for public release; distribution unlimited												
4 PERFORMING ORGANIZATION REP	R(S)	5. MONITORING ORGANIZATION REPORT NUMBER(S)												
6a. NAME OF PERFORMING ORGANIA Dana-Farber Cancer Ins		6b. OFFICE SYMBOL (If applicable)	7a. NAME OF MONITORING ORGANIZATION											
Nivision of Pediatric (6c. ADDRESS (City, State, and ZIP Coc	lne	<u></u>	75 4000555 (6)4 5440 4 4 705644											
44 Binney Street Boston, MA 02115	<i>Je)</i>		7b. ADDRESS (City, State, and ZIP Code)											
8a. NAME OF FUNDING/SPONSORING ORGANIZATION U.S. Army	Medical	8b Office SYMBOL (If applicable)	9. PROCUREMENT INSTRUMENT IDENTIFICATION NUMBER											
Res. and Develop. Comma 8c. ADDRESS (City, State, and ZIP Cod		<u> </u>		7-C-7009) C									
Fort Detrick Frederick, Maryland 211			PROGRAM ELEMENT NO. 62772A	PROJECT NO. 3S162-	TASK NO.	WORK UNIT ACCESSION NO.								
11. TITLE (Include Security Classificati			02//2/	772A874	AA	1151								
Retinal Derived Growth Factor: A Regulator of Neural Regeneration and Revascularization in Wound Healing. 12. PERSONAL AUTHOR(S)														
John A. Wagner														
	13b. TIME C	OVERED 1/86 TOL1/30/88	14. DATE OF REPORT (Year, Month, Day) 15. PAGE COUNT 1989 December 1 14											
Annual/Final 16. SUPPLEMENTARY NOTATION	PROMIT <u>E</u>	1700 ,0[1730708]	1989 Dec	ember 1		14								
Annual covers period of	time D	ecember 1, 1987	- November	30 , 19 88	_									
17. COSATI CODES	<u> </u>	18 SUBJECT TERMS (•									
	-GROUP	Factor: Nerve	blast Growth Factor; Retina Derived Growth e Regeneration; Chemotactic Agent; Sensory											
06 01		Nerves; RA II	I·()-,-											
19. ABSTRACT (Continue on reverse	if necessary	and identify by block n	umber)		•									
Retinal Derived Growth Factor (a heparin binding growth factor that is identical to aFGF (acidic Fibroblast Growth Factor)) stimulates neurite outgrowth in vitro. We have established a model system that will allow us to determine if a gradient of FGF can cause nerve regeneration in vivo and that this regeneration is predominantly due to increased neurite outgrowth by sensory nerves.														
20. DISTRIBUTION / AVAILABILITY OF WUNCLASSIFIED/UNLIMITED	ABSTRACT	RPT DTIC USERS		ECURITY CLASSIFIC lassified	ATION									
22a. NAME OF RESPONSIBLE INDIVID Mrs. Virginia Miller	UAL		1	(Include Area Code		FICE SYMBOL D-RMI-S								

Summary

Acidic Fibroblast Growth Factor (aFGF) is a peptide which has been purified from a number of tissues, but winch is present at very high concentration in the central nervous system. This growth factor is now emerging as an important neurotrophic agent that has effects on both cell survival and neurite extension by a number of nerve types. Experiments supported by this contract were designed: 1) to determine whether aFGF could act as a neurotropic factor (i.e., a factor that would be able to influence the directionality of neurite outgrowth by influencing nerves to grow toward a source of aFGF), or 2) if it could stimulate nerve regeneration in vivo. The experiments that have been done thus far do not provide any evidence that aFGF is a tropic factor; however, it is clear that aFGF can stimulate nerve regeneration in an in vivo model system. The potential therapeutic benefits of a regimen including aFGF remain to be evaluated.

SELE	Accession For NTIS GRA&I DTIC TAB Unannounced Justification
OOPY	By
	Dist Cpecial
	A-1

Foreword

Citations of commercial organizations and trade names in this report de not constitute an official Department of the Army endorsement or approval of the products or services of these organizations.

In conducting the research described in this report, the investigator adhered to the "Guide for the Care and Use of Laboratory Animals", prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Animal Resources, National Research Council (DHEW Publication No. (NIH) 78-23, Revised 1978).

Table of Contents

Frant 1	over		-					•							•	•			•		•	•	1336	1
Report	Cocum	nent:	ati	cn	ρ,	аģ	re	-	DD	1	.47	'3	•		•	•							PAGE	2
Summary			•						•		•	•	•	•		•	•						PAGE	3
Forewor	d			٠						•		•	•		•			•					PAGE	4
Table c	of Cor	tent	c s						•		•			•	•								PAGE	5
B od y of	Annu	al :	Rep	or	t		•			•	•	•	٠	•	•	•	•	•		•		•	PAGE	6-7
Figure	1							•			•		•		•		•	•					PAGE	8
Figure	2																						PAGE	8

Objective 1: To examine the effects of aFGF on the directionality of neurite extension by PC12 cells and sympathetic ganglia.

Rational and Experimental Design: We will determine aFGF (acidic Fibroblast Growth Factor) can influence the direction of neurite outgrowth from when it is slowly and continuously released from a polymer of ELVAX (ethylene vinal acetate).

Results: As reported in the first annual report, we have successfully prepared RDGF and incorporated it into a slow release ELVAX polymer. This system provided for a slow release of aFGF over a period of at least three days in a form that retained biological activity. Culturing of PC12 cells in the presence of such a polymer resulted in a stimulation of neurite outgrowth as would be expected; but, there was no directionality to this neurite outgrowth as measured in a number of different experiments. Thus we concluded that either aFGF does not function as a tropic or that the system that was established is not capable of maintaining an adequate gradient for this biological activity to manifest itself. Although this work did not provide any positive evidence for aFGF participating in a directional guidance mechanism, it would be a serious overinterpretation to suggest that we have excluded the possibility that aFGF might do so in some context. Because of the "negative" nature of the observations we made, it will not be possible to submit a manuscript describing these findings. We have, however, continued to explore other methods of establishing an FGF gradient and releasing FGF from substrates to determine these effects on neurite outgrowth.

Objective 2: To determine if aFGF will enhance the efficiency of nerve regeneration in vivo.

Work supported by this contract has demonstrated that aFGF enhances peripheral nerve regeneration in vivo. This work has been formulated into a manuscript and published. The paper was awarded the Peter J. Gingrass Memorial Award at the thirty-second annual meeting of the Plastic Surgery Research Conference.

Results: The sciatic nerve of Sprague-Dawley rats was transected and an entubulation repair was performed. Entubulation was performed either in the presence of collagen or collagen plus aFGF. The presence of aFGF clearly increased the number of myelinated axons that regenerated across a 5 mm nerve gap (figure 1). This increase in myelinated axons could result either from an increase in the number of nerves that were successfully capable of regenerating across the nerve gap or from a

bifurcation of axons. To distinguish these two possibilities and to determine the nature of the nerves that were regenerating across the nerve guide tube, we performed horseradish peroxidase labeling from a transection distal to the original repair. These studies confirm that there was an increase in the total number of HRP-labeled primary nerves in response to aFGF (figure 2). Interestingly, this increase was primarily due to an effect of aFGF on the ability of primary sensory neurons to regenerate through the nerve guide with a small and statistically insignificant effect on the motor nerves (figure 2). Thus we conclude that aFGF has the ability to stimulate the regeneration of sensory, but apparently not motor neurons.

Publications:

Cordeiro, P.G., Seckel, B.R., Lipton, S.A., D'Amore, P.A., Wagner, J.A.,, and Madison, R.D. (1989) Acidic fibroblast growth factor enhances peripheral nerve regeneration in vivo. J. of Plastic and Reconstructive Surgery, 83: 1013-1019.

Personnel supported by this contract:

John A. Wagner, Roger Madison, Patricia D'Amore, Brian Minsk, Holly Swanson, and Tom Horez.

No persons supported by this grant received a graduate degree during the period of support.

FIGURES:




Fig. 1. A comparison of myelinated axon counts in nerve guides filled with collagen alone (group I, n=6) versus collagen plus heparin (group II, n=6) versus collagen plus heparin plus aFGF (group III, n=12).




Fig. 2. A comparison of total horseradish peroxidase-labeled primary neurons, primary labeled sensory neurons, and primary labeled motor neurons in nerve guides filled with collagen plus heparin (group A, n=6) versus collagen plus heparin plus aFGF (group B, n=6).